On June 18, 2025, BrightSpring Health Services announced that its specialty pharmacy, Onco360®, has been selected as the national pharmacy partner for several newly approved therapies. These treatments target advanced ovarian and lung cancers, as well as neurofibromatosis type 1.
Onco360® will provide essential services including access, education, data, and expert support for these innovative treatments. BrightSpring President and CEO Jon Rousseau emphasized the rapid and pioneering work of their specialty teams in expanding care options for patients with serious, life-threatening conditions.
This strategic expansion reinforces Onco360®'s position as a leading independent Oncology Pharmacy. The partnerships are expected to contribute to BrightSpring's growth in the specialized and limited distribution drug market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.